Highlights

  • Capricor continues working through FDA review of Deramiocel, with November 22, 2026, established as the target action date.
  • Updated HOPE-3 extension findings showed a 76% slowing in upper-limb decline in a specified open-label comparison.
  • The company reported approximately USD 199 mn in cash, restricted cash and marketable securities at September 30, 2026.
  • Capricor is preparing Manufacturing and commercial operations for a potential launch, subject to regulatory approval.

Capricor Therapeutics (NASDAQ:CAPR) is drawing fresh attention after its latest developments put deramiocel fda review and hope-3 findings at the centre of its Investment narrative. The company’s disclosed milestones offer a clearer look at operating priorities, financial resources and what remains to be completed. Against that backdrop, shares gained 26.49% to USD 11.22 in the November 11, 2026 market figures. The distinction between progress already reported and milestones still planned remains essential when evaluating its next phase.

FDA Review Enters a Defining Stage

Capricor submitted an amendment to its Deramiocel Biologics License Application in August, adding two-year HOPE-3 open-label extension results and further analyses. The proposed refined indication focuses on upper-limb Impairment in patients older than nine years. The FDA designated the addition a major amendment and extended its target action date to November 22, 2026. Deramiocel remains investigational; a target date is not a guarantee of approval.

The review now brings the clinical evidence, manufacturing plans and potential commercial pathway together. Capricor has prioritised Deramiocel in its operations while awaiting clarity from US regulators.

Clinical Findings Underpin the Submission

At the October World Muscle Society Congress, Capricor presented an open-label comparison indicating that participants who crossed over from placebo to Deramiocel experienced 1.56 points less decline on the Performance of the Upper Limb 2.0 scale than in their prior placebo year. This corresponded to a 76% slowing in that comparison.

Cardiac findings from the HOPE-3 programme also received a pediatric cardiology research award from the American Heart Association in November. Such findings are part of the clinical discussion but do not substitute for the FDA’s assessment.

Resources and Launch Preparation

At September 30, Capricor reported approximately USD 199 mn in cash, restricted cash and marketable securities. Its third-quarter net loss was approximately USD 42.7 mn, compared with approximately USD 24.6 mn a year earlier.

The San Diego GMP Facility is positioned for an initial launch if approved, and Capricor is expanding cleanroom capacity with validation targeted in the first half of 2027. The company is also preparing patient-support, distribution and access arrangements.

The Next Milestones

The FDA target action date remains November 22. Capricor has also begun engagement with regulators in Europe and Japan, while programmes in younger Duchenne patients and Becker muscular dystrophy depend on subsequent US regulatory clarity.

The company expects existing resources to fund operations for at least the next twelve months under its current plan, excluding potential product sales and other non-operating financing opportunities.

What Comes Next

For Capricor Therapeutics, the near-term focus remains the milestones outlined in its latest announcements rather than an assumed outcome. The developments described above combine confirmed activity with expectations that remain subject to company execution, regulatory processes where applicable, and later reporting. Those distinctions will matter as subsequent updates provide more information about timing and progress.

Capricor Therapeutics shares traded at USD 11.22, up 26.49%, in the November 11, 2026 market figures.